TGAN vs. AIP, NVEC, VLN, CAN, QUIK, MX, AAOI, AXTI, ATOM, and SKYT
Should you be buying Transphorm stock or one of its competitors? The main competitors of Transphorm include Arteris (AIP), NVE (NVEC), Valens Semiconductor (VLN), Canaan (CAN), QuickLogic (QUIK), Magnachip Semiconductor (MX), Applied Optoelectronics (AAOI), AXT (AXTI), Atomera (ATOM), and SkyWater Technology (SKYT). These companies are all part of the "semiconductors & related devices" industry.
Arteris (NASDAQ:AIP) and Transphorm (NASDAQ:TGAN) are both small-cap computer and technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends, community ranking and media sentiment.
64.4% of Arteris shares are held by institutional investors. Comparatively, 66.5% of Transphorm shares are held by institutional investors. 33.7% of Arteris shares are held by insiders. Comparatively, 2.5% of Transphorm shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Arteris had 8 more articles in the media than Transphorm. MarketBeat recorded 11 mentions for Arteris and 3 mentions for Transphorm. Arteris' average media sentiment score of 0.94 beat Transphorm's score of 0.57 indicating that Transphorm is being referred to more favorably in the news media.
Arteris has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Transphorm has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500.
Arteris received 13 more outperform votes than Transphorm when rated by MarketBeat users. Likewise, 57.69% of users gave Arteris an outperform vote while only 50.00% of users gave Transphorm an outperform vote.
Arteris has a net margin of -69.70% compared to Arteris' net margin of -177.91%. Arteris' return on equity of -149.03% beat Transphorm's return on equity.
Transphorm has lower revenue, but higher earnings than Arteris. Arteris is trading at a lower price-to-earnings ratio than Transphorm, indicating that it is currently the more affordable of the two stocks.
Arteris currently has a consensus price target of $13.40, indicating a potential upside of 60.10%. Transphorm has a consensus price target of $5.75, indicating a potential upside of 17.11%. Given Transphorm's stronger consensus rating and higher possible upside, equities research analysts plainly believe Arteris is more favorable than Transphorm.
Summary
Arteris beats Transphorm on 11 of the 18 factors compared between the two stocks.
Get Transphorm News Delivered to You Automatically
Sign up to receive the latest news and ratings for TGAN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TGAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Transphorm Competitors List
Related Companies and Tools
